Currently, there are ongoing clinical trials to evaluate the efficacy of Trodelvy® in combination with prembolizumab, an immune checkpoint inhibitor targeted to programmed cell death-1 (PD-1) protein, (NCT04468061); talazoparib, a PARP inhibitor (NCT04039230); and several antineoplastics drugs such as gemcitabine, capecitabine and albumin-conjugated paclitaxel (NCT03424005) in patients with metastatic TNBC, and with eribulin, capecitabine, gemcitabine, and vinorelbine in patients with HER-2-positive or negative mammary tumors (NCT03901339). This evidence concerns the gene PDCD1 and breast cancer.